TBCRC030: A randomized, phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2-proficient triple-negative breast cancer (TNBC)—Evaluating the homologous recombination deficiency (HRD) biomarker.
Erica L. Mayer
No relevant relationships to disclose
Ines Vaz-Luis
No relevant relationships to disclose
Andrea L. Richardson
No relevant relationships to disclose
Charles M. Perou
No relevant relationships to disclose
Nadine M. Tung
No relevant relationships to disclose
Vandana Gupta Abramson
No relevant relationships to disclose
Carey K. Anders
No relevant relationships to disclose
Andres Forero-Torres
No relevant relationships to disclose
P. Kelly Marcom
No relevant relationships to disclose
Kathy Miller
No relevant relationships to disclose
Shannon Puhalla
No relevant relationships to disclose
Mothaffar F. Rimawi
No relevant relationships to disclose
Vered Stearns
No relevant relationships to disclose
Tiffany A. Traina
No relevant relationships to disclose
William Thomas Barry
No relevant relationships to disclose
Joshua Timothy Jones
Employment or Leadership Position - Myriad Genetics
Stock Ownership - Myriad Genetics
Kirsten Timms
Employment or Leadership Position - Myriad Genetics
Stock Ownership - Myriad Genetics
Anne-Renee Hartman
Employment or Leadership Position - Myriad Genetics
Stock Ownership - Myriad Genetics
Antonio C. Wolff
No relevant relationships to disclose
Eric P. Winer
No relevant relationships to disclose